国产99久久精品_欧美日本韩国一区二区_激情小说综合网_欧美一级二级视频_午夜av电影_日本久久精品视频

瑞士Philochem
Philogen成立于1996年,在瑞士與意大利的生物技術公司.Philogen的重點是生物制藥的新血管生成有關的疾病的治療發展。血管生成，即新血管的形成，是一個如癌癥，類風濕關節炎，老年性黃斑變性的許多嚴重病癥的特征。

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996 by the brothers Dario, Duccio, Giovanni Neri, with the initial mission to develop as products the promising human antibodies discovered by Prof. Dario Neri.

Philogen focuses on the development of new biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration.

The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumor neo-vasculature both in animal models and in cancer patients.

At present, Philogen has six promising anti-cancer antibody derivatives and an antibody-derivative for the treatment of rheumatoid arthritis in clinical studies. Two registrational studies (one in Phase III and one in Phase II) are in planning.

Our Zurich-based daughter company Philochem serving as the R&D unit isolates the most promising candidate products, while in Siena (Italy) the pharmaceuticals are produced according to GMP standards and advanced to clinical trials.

Philogen generates revenue from a diversified range of activities, has been profitable each year since 1999, has signed agreements with major pharmaceutical companies and owns a diversified portfolio of international patents.